Related Experiment Video
Updated: Nov 1, 2025
11:06
Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
Published on: April 7, 2023
2.3K
Bempedoic Acid: A First-in-Class Agent for Lowering Cholesterol Levels.
Candis M McGraw-Senat1, Nakoasha Dillard1, Taylor Guelda1
11Philadelphia College of Osteopathic Medicine, School of Pharmacy, Suwanee, Georgia.
The Senior Care Pharmacist
|June 19, 2021
Summary
Bempedoic acid offers a new nonstatin option for managing high cholesterol when statins are not tolerated or sufficient. This review examines its efficacy and safety, particularly for older adults.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Statin therapy is primary for hypercholesterolemia but has limitations.
- Some patients experience muscle-related side effects or fail to reach low-density lipoprotein cholesterol (LDL-C) goals with statins alone.
- Existing nonstatin agents have usage limitations.
Purpose of the Study:
- To review clinical trial findings on bempedoic acid.
- To discuss bempedoic acid's role in clinical practice.
- To evaluate bempedoic acid's use in older populations.
Main Methods:
- Review of Phase III clinical trials for bempedoic acid.
- Evaluation of safety and efficacy data.
- Discussion of bempedoic acid's mechanism of action (adenosine triphosphate citrate lyase inhibition).
Main Results:
- Bempedoic acid demonstrated promising safety and efficacy in Phase III trials.
- It functions by inhibiting adenosine triphosphate citrate lyase (ACL).
- Cardiovascular outcome data are pending.
Conclusions:
- Bempedoic acid is a novel nonstatin agent for lipid management.
- It may serve as an effective adjunctive therapy for specific patient groups.
- Further evaluation of its role in older adults is warranted.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.1K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.1K
01:26Atherosclerosis III: Management
87
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
87
01:23Antidepressant Drugs: MAOIs and Other Agents
521
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
521
01:27Bioavailability Enhancement: Drug Permeability Enhancement
44
Body:After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt...
44
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
840
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
840
01:25Antihypertensive Drugs: Direct Renin Inhibitors
965
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
965